CN108410873B - System and method for constructing LCAT gene knockout hamster model - Google Patents
System and method for constructing LCAT gene knockout hamster model Download PDFInfo
- Publication number
- CN108410873B CN108410873B CN201810201435.0A CN201810201435A CN108410873B CN 108410873 B CN108410873 B CN 108410873B CN 201810201435 A CN201810201435 A CN 201810201435A CN 108410873 B CN108410873 B CN 108410873B
- Authority
- CN
- China
- Prior art keywords
- hamster
- sgrna
- lcat
- cas9mrna
- constructing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150002998 LCAT gene Proteins 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000011553 hamster model Methods 0.000 title claims abstract description 23
- 238000003209 gene knockout Methods 0.000 title abstract description 13
- 241000699800 Cricetinae Species 0.000 claims abstract description 68
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 45
- 235000013601 eggs Nutrition 0.000 claims abstract description 13
- 230000008685 targeting Effects 0.000 claims abstract description 11
- 238000000520 microinjection Methods 0.000 claims abstract description 10
- 210000000805 cytoplasm Anatomy 0.000 claims abstract description 5
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 238000013518 transcription Methods 0.000 claims description 17
- 230000035897 transcription Effects 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 13
- 239000012043 crude product Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 101150038500 cas9 gene Proteins 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 9
- 238000012408 PCR amplification Methods 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 108010067770 Endopeptidase K Proteins 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 102000006382 Ribonucleases Human genes 0.000 claims description 4
- 108010083644 Ribonucleases Proteins 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 claims 6
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 claims 5
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 abstract description 27
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 abstract description 26
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 108020004414 DNA Proteins 0.000 description 32
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 235000012000 cholesterol Nutrition 0.000 description 9
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000012173 estrus Effects 0.000 description 5
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 108010025628 Apolipoproteins E Proteins 0.000 description 3
- 102000013918 Apolipoproteins E Human genes 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000002205 phenol-chloroform extraction Methods 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 2
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000004141 reverse cholesterol transport Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 238000008620 Cholesterol Assay Methods 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a system and a method for constructing a hamster model knocked out by Lecithin Cholesterol Acyltransferase (LCAT) gene, wherein the system comprises a hamster LCAT gene specific targeting sequence sgRNA and a PCR primer for amplifying the sgRNA. The method comprises the following steps: designing a targeting sequence specific to the hamster LCAT gene, and preparing the cas9mRNA and sgRNA; collecting and culturing hamster zygotes; microinjection: co-injecting the sgRNA and cas9mRNA into the cytoplasm of hamster zygotes; finally, the fertilized eggs after microinjection are implanted into a surrogate hamster, an F1 surrogate hamster is born, and a hamster model with an LCAT gene knockout is constructed through identification.
Description
Technical Field
The invention relates to the technical field of disease animal models and preparation thereof, in particular to a cardiovascular disease animal model and a construction method thereof, and especially relates to a construction method and a system of a Lecithin Cholesterol Acyltransferase (LCAT) gene knockout hamster.
Background
Lecithin-cholesterol acyltransferase (LCAT) is an esterifying enzyme that catalyzes free cholesterol in High-density lipoprotein (HDL), and receives cholesterol from peripheral tissues including arterial walls, which is transported to the liver for degradation, and is one of the key factors for reverse cholesterol transport. In the lipoprotein metabolic pathway, LCAT plays an important role in regulating the metabolism of cholesterol, triglycerides and phospholipids. The crowd investigation research finds that LCAT increasing has a protective effect on coronary heart disease; however, studies in mice have shown that overexpression of LCAT transgene promotes arteriosclerosis (As), and that knocking out LCAT reduces As, which is clearly contrary to LCAT's role in reverse cholesterol transport and the results of studies in the population. Therefore, it is necessary to use a humanized animal model to elucidate the important scientific question of delaying or promoting the development of coronary heart disease.
After the establishment of the genetically engineered mouse technology, although mice became the major model animal of animal models of disease, researchers increasingly recognized the difference between mouse disease and human disease. Therefore, the development and construction of humanized and humanized-like animal models for the development of transformation medicine research is also a direction for the development of biomedical fields in recent years. With the progress of the research of genetically engineered hamsters in recent years, the advantages of the genetically engineered hamsters in the research of metabolic cardiovascular diseases are gradually and widely re-recognized. Compared with mice and rabbits, the glycolipid metabolic mechanism of hamsters is more similar to that of human beings, including reactivity to high-fat diet, high-density lipoprotein (LDL) component in plasma lipid profile, Cholesterol Ester Transfer Protein (CETP), HL and ApoAII expression, ApoB100 edited by liver, and high-fructose feed can induce type 2 diabetes, so that the advantages of the hamsters in the research of metabolic cardiovascular diseases are very clear.
Based on hamster anthropomorphic characteristics, LCAT gene knockout (LCAT-/-) and transgenosis of hamsters can provide a relatively clear answer for the influence of LCAT on As in disputes and provide a theoretical basis for further intervention method research.
Disclosure of Invention
The invention aims to provide a system and a method for constructing an LCAT gene knockout hamster model. The embodiment of the invention applies a high-efficiency genome editing CRISPR/Cas9 technology to construct an LCAT gene knockout anthropomorphic hamster animal model for solving the problem of the controversial relationship between LCAT and atherosclerosis in clinical and basic researches.
In order to achieve the purpose, the embodiment of the invention adopts the technical scheme that:
a system for constructing a LCAT gene knockout hamster model, the system comprising hamster LCAT gene specific targeting sequences and sgrnas:
the hamster LCAT gene specific targeting sequence is shown as SEQ ID NO. 1;
preparation of the sgRNA: adopting artificial sequences shown in SEQ ID NO. 2 and SEQ ID NO. 3, carrying out PCR amplification, taking a 124bp DNA fragment in an amplification product as a DNA template of the sgRNA, and carrying out in-vitro transcription on the obtained DNA template of the sgRNA to obtain a sgRNA crude product.
Optionally, the system further comprises cas9mRNA prepared by the steps of: the DNA template of cas9mRNA is obtained by adopting PXT7 plasmid containing humanized cas9 cDNA and purifying through XbaI restriction endonuclease action, and the obtained DNA template of cas9mRNA is obtained through in vitro transcription to obtain cas9mRNA crude product.
Alternatively, in the preparation of cas9 mRNA:
the DNA template purification method of cas9mRNA comprises the following steps: treating PXT7 plasmid with XbaI restriction endonuclease, treating with proteinase K for 20-50min, extracting with phenol-chloroform, and precipitating with ethanol;
and/or the purification method of the obtained cas9mRNA crude product comprises the following steps: the cas9mRNA crude product is extracted by phenol-chloroform, precipitated by isopropanol and dissolved by water without RNA enzyme, thus obtaining cas9mRNA with the concentration of 200 and 800 ng/mul.
Alternatively, the conditions for DNA template transcription of cas9mRNA are: using the mMESSAGE mMACHINE T7 kit, the reaction was carried out at 37 ℃ for 1 to 3 hours.
Optionally, the reaction conditions for PCR amplification are:
98℃30s;
35 cycles of 98 ℃ for 10s,56 ℃ for 30s and 72 ℃ for 15 s;
72℃10min。
alternatively, the conditions for DNA template transcription of sgrnas are: the reaction was carried out at 37 ℃ for 3-5h using Megascript T7 Kit.
Alternatively, in the preparation of sgrnas:
the method for selecting and purifying the DNA template of the obtained sgRNA comprises the following steps: subjecting the PCR product to agarose gel electrophoresis, recovering a 124bp DNA band by using a gel recovery kit, treating for 20-50min by using proteinase K, extracting by using phenol-chloroform, and precipitating by using ethanol to obtain a DNA template of the sgRNA; and/or
The purification method of the obtained sgRNA crude product comprises the following steps: purification was performed using the MEGAclear Kit, with no RNase water dissolved to a concentration of 100-500 ng/. mu.l sgRNA.
The embodiment of the invention also provides a method for constructing the LCAT gene knockout hamster model, which comprises the following steps:
step one, designing a hamster LCAT receptor gene specific targeting sequence shown as SEQ ID NO. 1; preparing cas9mRNA from PXT7 plasmid containing humanized cas9 cDNA, and preparing sgRNA by PCR reaction and transcription by adopting artificial sequences shown as SEQ ID NO:2 and SEQ ID NO: 3;
step two, collecting and culturing hamster zygotes;
step three, microinjection: injecting the sgRNA and cas9mRNA prepared in the first step into cytoplasm of hamster fertilized eggs;
and step four, implanting the fertilized eggs subjected to microinjection into surrogate pregnant hamsters, and identifying the F1 surrogate hamsters after birth.
The beneficial effect that adopts above-mentioned technical scheme to produce lies in: the sgRNA sequence adopted in the embodiment of the invention is efficient and is not easy to miss; the operation is simple, the efficiency is high, and the fatality rate is low; the personified LCAT-/-hamster model provided by the embodiment of the invention has important significance for determining the relation between LCAT and atherosclerosis, especially coronary arteriosclerosis.
Drawings
Fig. 1 is a hamster gene sequence, wherein the sgRNA recognition sites on the second exon of the LCAT gene are shown in italic font, the PAM sequence is in italic bold font and the mutated portion is underlined;
FIGS. 2A-2C are LCAT genotypes after successful hamster model construction, respectively, and compared to normal hamster genotypes, wherein italic fonts are sgRNA positions, italic bold fonts are PAM sequences, and- -are missing portions;
FIG. 3 is a DNA gel electrophoresis of LCAT deleted Δ 12bp hamster tissue after PCR amplification, the length of the deleted fragment DNA is 108bp, and the three genotypes of wild type (wt), heterozygote (+/-), and homozygote (-/-);
FIG. 4 shows a graph of total cholesterol and triglyceride levels in plasma and HDL-C levels in homozygotes of the LCAT gene lacking bases Δ 6bp, Δ 12bp, and Δ 56bp, and a wild-type control hamster, respectively;
FIGS. 5A-C are phenotyping hamsters lacking Δ 56 homozygous for testing plasma cholesterol levels;
FIGS. 6A and 6B are lipoprotein maps in LCAT gene-deleted hamsters and wild-type hamsters TC and TG, respectively, wherein the LCAT knockout hamster is (-/-), and the wild-type hamster is (WT);
FIGS. 7A-C are western blot analysis of hamster plasma apolipoproteins ApoB100, ApoE, ApoAI and LCAT activity profiles in LCAT gene-deleted hamster and wild-type hamster plasma, respectively;
FIG. 8 is a graph of atherosclerotic lesions, wherein A is a representative graph representing an atherosclerotic lesion; and B, quantitatively detecting the arteriosclerosis lesion area.
Detailed Description
In order to make the technical problems, technical solutions and advantageous effects to be solved by the present invention more clearly apparent, the present invention is further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The test methods used in the following examples are all conventional methods unless otherwise specified; the materials, reagents and the like used are, unless otherwise specified, commercially available reagents and materials.
The basic concept of the embodiment of the invention is as follows: based on hamster LCAT Gene information (Gene ID:101823034), cas9mRNA and sgRNA were constructed based on the design of guide RNA targeting atctcaatatgtttctacccctgg sequence in its second exon as sgRNA sequence.
Example 1
A system for constructing a LCAT gene knockout hamster model comprising hamster LCAT gene specific targeting sequences, cas9mRNA and sgRNA:
the hamster LCAT gene specific targeting sequence is shown as SEQ ID NO. 1;
preparation of the cas9 mRNA:
adopting a PXT7 plasmid containing humanized cas9 cDNA, performing XbaI restriction endonuclease action, and purifying to obtain a DNA template of cas9mRNA, wherein the DNA template of cas9mRNA is subjected to in vitro transcription to obtain a cas9mRNA crude product;
preparation of the sgRNA: adopting artificial sequences shown in SEQ ID NO. 2 and SEQ ID NO. 3 as primers and templates, performing PCR amplification, taking a 124bp DNA fragment in an amplification product as a DNA template of the sgRNA, and performing in-vitro transcription on the DNA template of the sgRNA to obtain a sgRNA crude product.
In NCBI (National Center for Biotechnology Information ), hamster whole genome sequencing and splicing work has been very completed, databases have been established, and the gene modification model preparation and identification work of this example was basically completed based on the databases. The LCAT Gene information (Gene ID:101823034) in the database was found to design the target sequence position of the sgRNA in its second exon, see FIG. 1 and SEQ ID NO: 1.
In this example, cas9DNA template used in the preparation of cas9mRNA was PXT7 plasmid containing humanized cas9 cDNA. Before transcription, the PXT7 plasmid was fully linearized by the action of XbaI restriction enzymes. After the reaction was terminated, the sample was treated with proteinase K for 30min to remove RNase as much as possible. Further phenol-chloroform extraction and ethanol precipitation are carried out to obtain the DNA template of cas9 mRNA.
The DNA template of cas9mRNA was in vitro transcribed to obtain cas9 mRNA. Wherein the kit for in vitro transcription is the mMESSAGE mMACHINE T7 kit (Ambion) kit. The transcription system was fully reacted at 37 ℃ for 2 hours. Cas9mRNA obtained by the reaction was purified by phenol-chloroform extraction, precipitated with isopropanol, and dissolved in RNase-free water to a concentration of 500 ng/. mu.l. Stored in a-80 ℃ freezer for use in constructing microinjection molds.
The primers shown in SEQ ID NO. 2 and SEQ ID NO. 3 are mutually taken as templates, and the method for carrying out PCR amplification comprises the following steps: the reaction is carried out in a 50 mu l system under the reaction condition of 98 ℃ for 30 s; 35 cycles of 98 ℃, 10s,56 ℃, 30s,72 ℃ and 15 s; 10min at 72 ℃. The PCR product is subjected to agarose gel electrophoresis, and a 124bp DNA band is recovered using a gel recovery kit, such as TAKARA kit. Then treated with proteinase K for 30min to remove RNase from the sample as much as possible. Further, phenol-chloroform extraction and ethanol precipitation are carried out to obtain the DNA template of the sgRNA.
The DNA template of the resulting sgRNA is transcribed using an in vitro transcription kit, such as Megascript T7 kit (ambion) kit. The transcription system was fully reacted at 37 ℃ for 4 hours. The sgRNA obtained from the reaction was purified using the MEGAclear Kit (ambion). RNase-free water was dissolved to a concentration of 200 ng/. mu.l. Stored in a-80 ℃ freezer for use in constructing microinjection molds.
The system of the embodiment can be used for constructing hamster models of LCAT gene knockout.
Example 2
In this example, a method for constructing a hamster knockout LCAT gene model using the system of example 1 will be described by taking a wild hamster obtained from experimental animal technologies of viton, beijing as an example. In this example, experimental plans and procedures such as preparation and analysis of hamster models were examined by ethical committee experimental animal ethics.
The wild type hamsters were raised to clean grade standards. Keeping the humidity at 50-60% and the temperature at 22-24 ℃. The illumination period is 6:00-20:00 illumination and 20:00-6:00 darkness.
The specific method for preparing hamster model from wild hamster comprises the following steps:
step one, according to the system of example 1, the hamster LCAT gene specific target sequence was designed, and the cas9mRNA and sgRNA were prepared.
Step two, collecting and culturing hamster zygotes
Selecting 8-12 weeks old female mice to induce superovulation. The estrus cycle of hamsters was four days, and on the second day of the cycle, i.e., after disappearance of oestrus, Pregnant Mare Serum Gonadotropin (PMSG) was intraperitoneally injected at a concentration of 125U/kg. The first night of the next estrus cycle 19 points were mated overnight with male mice in cages. The female mice were sacrificed by intraperitoneal injection of excess pentobarbital sodium at 14 pm the next day after cage combination. The oviduct was dissected and placed in M2 medium (Sigma-Aldrich, St. Louis, MO, USA) preheated at 37 ℃. Under a dissecting microscope, tearing the ampulla of the expanded oviduct, allowing the deposit containing the fertilized eggs to flow out, and collecting the fertilized eggs.
The in vitro culture medium for hamster zygotes was HECM-10(NaCl 113.8mM, KCl 3mM, NaHCO)325mM sodium lactate 4.5mM CaCl21mM,MgCl22mM, 0.01mM of glutamic acid, 0.2mM of glutamine, 0.01mM of glycine, 0.01mM of histidine, 0.01mM of lysine, 0.01mM of proline, 0.01mM of serine, 0.01mM of asparagine, 0.01mM of aspartic acid (aspartic acid), 0.01mM of cysteine (cysteine), 0.5mM of taurine (taurine), 0.003mM of pantothenate, 0.1mg/ml of polyvinyl alcohol). The HECM-10 culture drops were overlaid with paraffin oil. The culture temperature of fertilized eggs is 37.5 ℃, and CO is2The concentration was 10% for culture.
Step three, microinjection: co-injecting the sgRNA and cas9mRNA of step one into the cytoplasm of hamster zygotes.
Injection drops were prepared and a drop of 100 μ l M2 medium was added to the injection dish, sealed in mineral oil. All fertilized eggs leave the incubator for less than 15 minutes. sgRNA and cas9mRNA were co-injected into the cytoplasm at injection concentrations of 10 ng/. mu.l and 20 ng/. mu.l. The fertilized eggs after injection are cultured in an incubator for 1-2 hours and then are used for retransfusion to surrogate mother rats.
And step four, implanting the fertilized eggs subjected to microinjection into surrogate pregnant hamsters, and identifying the F1 surrogate hamsters after birth.
Female mice with the same age and estrus cycle as the ovine hamster were selected as surrogate hamsters. The surrogate mouse estruses 19 points later in the first day and mates with the male mouse in a cage overnight. The next day, the injected fertilized eggs are implanted into the surrogate mouse from the umbrella mouth of the fallopian tube. 15 fertilized eggs were implanted into each fallopian tube.
After one week of born hamster age, genome DNA extracted from skin tissue, toe tissue or blood cells of the born hamster is taken, a target fragment is amplified by PCR, primers are upstream 5'-CAGACGCCAGTCATAGGGTG-3' (SEQ ID NO:4) and downstream 5'-CCAGAACAAAAGCTGGTGCC-3' (SEQ ID NO:5), a specific band is obtained by electrophoresis detection after PCR, the sequence is divided into a sequence and a chromatographic peak map, the mutation position is determined, the mutant hamster is further subjected to sequence verification, a PCR product is linked to a T vector and transformed into a competent cell, the competent cell is inoculated to an LB culture medium plate added with ampicillin, the LB culture medium plate is incubated at 37 ℃ for 12h, 20 monoclonal colonies are randomly picked and inoculated to an LB liquid culture medium, after 12h incubation at 37 ℃, a bacterial solution is subjected to sequencing, the sequence and the chromatographic peak map are analyzed, the number and the position of base mutation and the mutation type which can be generated are determined, the damaged DNA is directly connected from the tail end or recombined to repair after digestion of the specific site by virtue of cas9 endonuclease, so that LCAT gene mutation types of various different in vivo are generated, after digestion of the specific site enzyme, the damaged DNA is subjected to end direct connection or recombination, the end recombination is repaired, and the LCAT gene mutation types of the mutant strains are obtained, and are subjected to hybridization of wild strain, and the tail strain obtained by a tail clone DNA obtained by a method of a clone strain obtained by a method of PCR amplification method, a target fragment amplification method, a primer, a target fragment amplification primer, a.
The free cholesterol assay kit (priley biotechnology limited) measures the amount of free cholesterol in plasma continuing with the most phenotypically clear △ 56bp strain homozygous hamster, the plasma was tested and found that in the presence of a significant decrease in HDL-C (high density lipoprotein cholesterol) (fig. 5A), the HDL/TC ratio (fig. 5B) also showed almost no HDL component in total plasma cholesterol, in the absence of a significant change in total cholesterol, plasma free cholesterol (free cholesterol) (fig. 5C) was significantly elevated, thus a positive significant decrease in cholesterol esters indicates a t-test statistical test p < 0.001.
Lipid component in plasma lipoprotein is detected by using Fast Protein Liquid Chromatography (FPLC) instrument and hyperse 6HR10/30 chromatographic column to separate plasma lipoprotein component firstly. 200 μ l of plasma was loaded through a 0.22 μm syringe filter and fractions were automatically collected at 0.5 mL/min for a total of 40 fractions, 500 μ l each. The collected 40-tube fractions were measured for cholesterol (TC) and Triglyceride (TG) concentrations, respectively, and plotted as a lipoprotein profile, referring to fig. 6A and 6B, where fig. 6A shows the peaks of the respective fractions as Very Low Density Lipoprotein (VLDL), Low Density Lipoprotein (LDL), and High Density Lipoprotein (HDL), respectively, and the peaks of the respective fractions in fig. 6B are located at the same positions as those in a. The results show a significant increase in VLDL fraction and a significant decrease in HDL fraction in LCAT knockout hamsters.
Western blot analysis of hamster plasma apolipoproteins ApoB100, ApoE, ApoAI, fig. 7A is a protein band displayed by chemiluminescence method after ultracentrifugation and defatting of plasma lipoproteins, SDS-PAGE electrophoresis, hybridization with the corresponding apolipoprotein antibodies, and fig. 7B is a bar graph after scanning quantification. The results showed that LCAT knockout hamster (-/-) plasma ApoB100 was significantly increased, ApoAI was not detectable, and ApoE was not significantly changed. The LCAT activity was measured using a cholesterol acyltransferase activity assay kit (MAK107) from SIGMA, and it was found that LCAT activity in plasma of a knockout homozygous (LCK) hamster was significantly reduced compared to a Wild Type (WT) hamster. Denotes t-test statistical test p < 0.001.
The above results show that: the LCAT knockout hamster model was successfully prepared using the method of this example. Using this LCAT gene knockout hamster model, given 12 weeks of high fat diet, aortic atherosclerotic lesions were significantly more elevated in LCAT mutant hamsters than in normal control hamsters, suggesting that LCAT gene deficiency may contribute to atherosclerotic lesions, as shown in fig. 8: a is a representative diagram showing arteriosclerotic lesions; and B, quantitatively detecting the arteriosclerosis lesion area.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
<110> Hebei Yiweiwa Biotech Ltd
<120> System and method for constructing LCAT Gene knockout hamster model
<130>2018.02.27
<160>5
<170>PatentIn version 3.5
<210>1
<211>24
<212>DNA
<213> target sequence
<400>1
atctcaatat gtttctaccc ctgg 24
<210>2
<211>64
<212>DNA
<213>CRISPR-Forward
<400>2
gaaattaata cgactcacta tagatctcaa tatgtttcta ccccgtttta gagctagaaa 60
tagc 64
<210>3
<211>80
<212>DNA
<213>sgRNA-Reverse
<400>3
aaaagcaccg actcggtgcc actttttcaa gttgataacg gactagcctt attttaactt 60
<210>4
<211>20
<212>DNA
<213> Artificial sequence
<400>4
<210>5
<211>20
<212>DNA
<213> Artificial sequence
<400>5
Claims (9)
1. A system for constructing a hamster model knockout of the LCAT gene, the system comprising a hamster LCAT gene-specific targeting sequence and sgRNA:
the hamster LCAT gene specific targeting sequence is shown as SEQ ID NO. 1;
preparation of the sgRNA: adopting artificial sequences shown in SEQ ID NO. 2 and SEQ ID NO. 3, carrying out PCR amplification, taking a 124bp DNA fragment in an amplification product as a DNA template of the sgRNA, and carrying out in-vitro transcription on the obtained DNA template of the sgRNA to obtain a sgRNA crude product.
2. The system for constructing a LCAT knockout hamster model of claim 1, further comprising cas9mRNA prepared by the steps of: the DNA template of cas9mRNA is obtained by purifying PXT7 plasmid containing humanized cas9 cDNA through XbaI restriction endonuclease action, and the obtained DNA template of cas9mRNA is obtained through in vitro transcription to obtain cas9mRNA crude product.
3. The system for constructing a LCAT knockout hamster model of claim 2, wherein in the preparation of cas9 mRNA:
the DNA template purification method of cas9mRNA comprises the following steps: treating PXT7 plasmid with XbaI restriction endonuclease, treating with proteinase K for 20-50min, extracting with phenol-chloroform, and precipitating with ethanol;
and/or the purification method of the obtained cas9mRNA crude product comprises the following steps: the cas9mRNA crude product is extracted by phenol-chloroform, precipitated by isopropanol and dissolved by water without RNA enzyme, thus obtaining cas9mRNA with the concentration of 200 and 800 ng/mul.
4. The system of claim 2, wherein the conditions for in vitro transcription of the DNA template for cas9mRNA are: using the mMESSAGE mMACHINE T7 kit, the reaction was carried out at 37 ℃ for 1 to 3 hours.
5. The system for constructing a LCAT knockout hamster model according to claim 1, wherein the reaction conditions for the PCR amplification are:
98℃30s;
35 cycles of 98 ℃ for 10s,56 ℃ for 30s and 72 ℃ for 15 s;
72℃10min。
6. the system of claim 1, wherein the conditions for in vitro transcription of the DNA template of the sgRNA are: the reaction was carried out at 37 ℃ for 3-5h using Megascript T7 Kit.
7. The system for constructing a hamster model knockout LCAT gene of claim 1, wherein in the preparation of sgRNAs,
the method for selecting and purifying the DNA template of the obtained sgRNA comprises the following steps: subjecting the PCR product to agarose gel electrophoresis, recovering a 124bp DNA band by using a gel recovery kit, treating for 20-50min by using proteinase K, extracting by using phenol-chloroform, and precipitating by using ethanol to obtain a DNA template of the sgRNA; and/or
The purification method of the obtained sgRNA crude product comprises the following steps: purification was performed using the MEGAclear Kit, with no RNase water dissolved to a concentration of 100-500 ng/. mu.l sgRNA.
8. A method for constructing a LCAT knock-out hamster model using the system of any of claims 1 to 7, comprising the steps of:
step one, designing a hamster LCAT receptor gene specific targeting sequence shown as SEQ ID NO. 1; preparing cas9mRNA from PXT7 plasmid containing humanized cas9 cDNA, and preparing sgRNA by PCR reaction and in vitro transcription by adopting artificial sequences shown as SEQ ID NO. 2 and SEQ ID NO. 3;
step two, collecting and culturing hamster zygotes;
step three, microinjection: injecting the sgRNA and cas9mRNA prepared in the first step into cytoplasm of hamster fertilized eggs;
and step four, implanting the fertilized eggs subjected to microinjection into surrogate pregnant hamsters, and identifying the F1 surrogate hamsters after birth.
9. The method of constructing a LCAT knockout hamster model of claim 8, wherein: in step three, the injection concentration of sgRNA and cas9mRNA was 10 ng/. mu.l and 20 ng/. mu.l, respectively.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810201435.0A CN108410873B (en) | 2018-03-12 | 2018-03-12 | System and method for constructing LCAT gene knockout hamster model |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810201435.0A CN108410873B (en) | 2018-03-12 | 2018-03-12 | System and method for constructing LCAT gene knockout hamster model |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108410873A CN108410873A (en) | 2018-08-17 |
CN108410873B true CN108410873B (en) | 2020-05-26 |
Family
ID=63131065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810201435.0A Active CN108410873B (en) | 2018-03-12 | 2018-03-12 | System and method for constructing LCAT gene knockout hamster model |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108410873B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114990158B (en) * | 2022-05-19 | 2023-05-26 | 北京大学 | Construction method of SCARA3 gene knockout hamster model |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107022572A (en) * | 2016-02-01 | 2017-08-08 | 河北伊维沃生物科技有限公司 | The genetic engineering hamster that ldl receptor gene is knocked out |
-
2018
- 2018-03-12 CN CN201810201435.0A patent/CN108410873B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107022572A (en) * | 2016-02-01 | 2017-08-08 | 河北伊维沃生物科技有限公司 | The genetic engineering hamster that ldl receptor gene is knocked out |
Non-Patent Citations (5)
Title |
---|
Disruption of the Murine Lecithin:Cholesterol Acyltransferase Gene Causes Impairment of Adrenal Lipid Delivery and Up-regulation of Scavenger Receptor Class B Type I;Dominic S. Ng等;《The Journal of Biological Chemistry》;19970620;第272卷(第25期);第15777-15781页 * |
In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice;James W. Furbee等;《Journal of Lipid Research》;20021231;第428-437页 * |
Lecithin : Cholesterol acyltransferase (LCAT) knockout mice: A new animal model for human LCAT-deficiency;N. Sakai等;《11th International Symposium on Atherosclerosis》;19971031;第372-373页 * |
Loss of LCAT activity in the golden Syrian hamster elicits pro-atherogenic dyslipidemia and enhanced atherosclerosis;Zhao Dong等;《Metabolism Clinical and Experimental》;20180630;第245-255页 * |
Rabbit models for the study of human atherosclerosis: From pathophysiological mechanisms to translational medicine;Jianglin Fan等;《Pharmacology & Therapeutics》;20140930;第146卷;第104-119页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108410873A (en) | 2018-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108660161B (en) | Method for preparing chimeric gene-free knockout animal based on CRISPR/Cas9 technology | |
US11317610B2 (en) | Method of constructing zebrafish notch1a mutants | |
CN105647969B (en) | Method for breeding zebra fish with stat1a gene deletion by gene knockout | |
CN108148873A (en) | A kind of CAV-1 gene delections zebra fish and preparation method thereof | |
CN108753783A (en) | The construction method of Sqstm1 full genome knock-out mice animal models and application | |
Zhou et al. | Programmable base editing of the sheep genome revealed no genome-wide off-target mutations | |
CN109234278B (en) | Kit and method for constructing ApoC2 gene knockout hamster model | |
EP3381278B1 (en) | Method for preparing a canine model of atherosclerosis | |
CN110885858B (en) | Construction method and application of Amy1 gene knockout mouse animal model | |
CN106282231B (en) | Construction method and application of mucopolysaccharide storage disease type II animal model | |
CN110551759A (en) | Composition and method for improving recombination efficiency of transgenic cells | |
CN108048486A (en) | A kind of method of gene knockout selection and breeding fhl1b Gene Deletion zebra fish | |
US10932454B2 (en) | LDL receptor gene knockout, genetically-engineered hamster | |
CN113736787A (en) | gRNA of targeted mouse Atp7b gene and method for constructing Wilson disease mouse model | |
CN111979266A (en) | Construction method and application of PCSK9 humanized mouse model | |
CN108410873B (en) | System and method for constructing LCAT gene knockout hamster model | |
CN111778278B (en) | Construction method and application of Slfn 4-deleted atherosclerosis model mouse | |
CN110066805A (en) | The method of gene knockout breeding adgrf3b Gene Deletion zebra fish | |
CN109456996B (en) | Kit and method for constructing ABCA1 gene knockout hamster model | |
CN114480497B (en) | Construction and application method of ep400 gene knockout zebra fish heart failure model | |
CN116473020A (en) | Construction method and application of Macrosialin gene-deleted atherosclerosis mouse model | |
CN116083482A (en) | Construction method of B cell conditional knockout DHX9 gene mouse model | |
CN115261360A (en) | Method for constructing gata6 gene knockout zebra fish model | |
CN116083492A (en) | Preparation method of csde1 gene deletion zebra fish mutant and construction method of zebra fish hematopoietic stem cell development defect model | |
CN114085840A (en) | Construction method of CAMTA2 gene-deleted zebra fish |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230614 Address after: 102200 15 buildings including 10 buildings on the south west side of West Railway Station Road, Changping District, Beijing Patentee after: BEIJING HFK BIOSCIENCE Co.,Ltd. Address before: 050000 No. 198 Xiangjiang Road, high tech Zone, Shijiazhuang City, Hebei Province Patentee before: HEBEI INVIVO BIOTECH Inc. |